An Evaluation of Treatment Patterns for Osteoporosis and Outcomes After a Fragility Fracture in a Real-World Setting.

Singer AJ, Williams SA, Pearman L, Wang Y, Pyrih N, Jeray K

Journal of orthopaedic trauma4 Nov 2022Cited by 9 (Europe PMC)

PMID36730766PMCIDPMC9988223DOI10.1097/bot.0000000000002515PepBankPUB-36730766

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyOther
In patients after fragility fracture, abaloparatide treatment duration was 6.5 months.
In plain wordsIn patients after fracture, abaloparatide treatment lasted 6.5 months.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTreatment duration
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Treatment duration
6.5 months
abaloparatide
Source sentences
Summary
Treatment duration and persistence were low for all treatments ranging from 6.5 months with 19.6% persistent for abaloparatide to 11.3 months with 45.0% persistent for denosumab.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study used real-world data for patients (≥50 years), including pharmacy claims linked to commercial and Medicare medical claims from Symphony Health Patient Source.
Report a problemFND-3673076601
02HumanObservational studyOther
In patients after fragility fracture, persistence with abaloparatide was 19.6%.
In plain wordsIn patients after fracture, 19.6% persisted with abaloparatide treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTreatment persistence
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Persistence
19.6%
abaloparatide
Source sentences
Summary
Treatment duration and persistence were low for all treatments ranging from 6.5 months with 19.6% persistent for abaloparatide to 11.3 months with 45.0% persistent for denosumab.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study used real-world data for patients (≥50 years), including pharmacy claims linked to commercial and Medicare medical claims from Symphony Health Patient Source.
Report a problemFND-3673076602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.